Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gentium jump on CHMP reversal for Defitelio

Shares of Gentium S.p.A. (NASDAQ:GENT) jumped $4.85 (50%) to $14.61 on Friday after EMA's CHMP backed approval of Defitelio defibrotide

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE